HCSC Coverage Is a Win for New-Gen Cardiac Telemetry Device

Ten years after the launch of a mobile outpatient cardiac telemetry device from medtech company BioTelemetry, Inc., insurer Health Care Service Corp. (HCSC) has included it in its medical coverage policy. Pennsylvania-based manufacturer BioTelemetry revealed the coverage decision in a February earnings call, saying that the move was the result of a non-stop effort to flip a small holdout of insurers. BioTelemetry says about 95% of payers cover the diagnostic device, and many without step therapy requirements that mandate patients try other devices first.

The mobile outpatient cardiac telemetry (MOCT) device is perhaps one of the most recent medical developments used for diagnosing heart rhythm and rate abnormalities. These problems — the heart pumping too slow or too fast — can cause sudden cardiac arrest, stroke and/or death.

0 Comments
© 2024 MMIT
Freelance Reporter

Freelance Reporter Freelance Reporter

Related Posts

medicare-part-c
May 17

Medicare, Medicaid Segments May Be a ‘Mess,’ but Bounce-Back Expected

READ MORE
hospital-hallway
May 17

As Hospitals’ Commercial Prices Keep Rising, Experts Float Solutions

READ MORE
businessman-viewing-news-update-journalism-headline-on-a-laptop
May 17

News Briefs: CMS Extends Medicaid Redetermination Deadline

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today